Ocular therapeutix™ announces first patients enrolled in phase 3 sol-r wet amd study

Sol-r evaluates repeat axpaxli™ dosing for wet age-related macular degeneration (wet amd) global non-inferiority study comparing axpaxli, dosed every six months, to 2 mg aflibercept every eight weeks bedford, mass., july 30, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq: ocul, “ocular”, the “company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the first patients have been enrolled in the phase 3 sol-r clinical trial evaluating repeat dosing of axpaxli™ (axitinib intravitreal implant, also known as otx-tki) for the treatment of patients with wet age-related macular degeneration (wet amd).
SOL Ratings Summary
SOL Quant Ranking